Onivyde Approval History
- FDA approved: Yes (First approved October 22nd, 2015)
- Brand name: Onivyde
- Generic name: irinotecan liposomal
- Dosage form: Injection
- Previous name: MM-398
- Company: Merrimack Pharmaceuticals, Inc.
- Treatment for: Pancreatic Cancer
Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan indicated for the treatment of post-gemcitabine metastatic adenocarcinoma of the pancreas.
FDA Approval: The effectiveness of Onivyde was demonstrated in a study of 417 patients with metastatic pancreatic adenocarcinoma whose cancer had progressed following gemcitabine-based therapy. Patients treated with Onivyde plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin.
Mechanism: Onivyde is a novel encapsulation of irinotecan in a liposomal formulation. SN-38, the active metabolite of irinotecan, inhibits topoisomerase I (an essential enzyme involved in DNA transcription and replication) and promotes cell death.
Administration: Onivyde is administered by intravenous infusion over 90 minutes every 2 weeks, prior to leucovorin and fluorouracil. Onivyde is not approved for use as a single agent.
Side Effects: Common side effects reported in clinical trials included diarrhea, fatigue, vomiting, nausea, decreased appetite, inflammation in the mouth (stomatitis) and fever (pyrexia). Onivyde was also found to cause lymphopenia and neutropenia.
Additional Information: The labeling for Onivyde includes a boxed warning to alert health care professionals about the risks of potentially life-threatening neutropenia and severe diarrhea. Onivyde may cause severe hypersensitivity reactions including anaphylactic reactions. Onivyde can cause fetal harm when administered to a pregnant woman, so females of reproductive potential should use effective contraception at all times during treatment, and for one month after the final dose. Males with female partners of reproductive potential should use effective contraception at all times during treatment, and for four months after the final dose. Nursing women should not breastfeed at any time during treatment, and for one month after the final dose.
Development History and FDA Approval Process for Onivyde
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.